ReviewCanadian family physician Medecin de famille canadien2012
Update on the clinical use of buprenorphine: in opioid-related disorders.
Review in Canadian family physician Medecin de famille canadien, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 47 citations in OpenAlex.
- Treatment outcomes in opioid dependent patients with different buprenorphine/naloxone induction dosing patterns and trajectories.The American journal on addictions · 2015Trial
- Discovery of 6α-Thiazolylcarboxamidonaltrexamine Derivative (NTZ) as a Potent and Central Nervous System Penetrant Opioid Receptor Modulator with Drug-like Properties for Potential Treatment of Opioid Use Disorder.ACS pharmacology & translational science · 2024Article
- The Effect of Different Opioids on Acid-Base Balance and Blood Gas Analysis in Hospitalized Dogs.Frontiers in veterinary science · 2022Article
- Documented opioid use disorder and its treatment in primary care patients across six U.S. health systems.Journal of substance abuse treatment · 2020Article
- Barriers and facilitators to buprenorphine use for opioid agonist treatment: protocol for a scoping review.BMJ open · 2019Article
- Design, Synthesis, and Biological Evaluation of the Third Generation 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan (NAP) Derivatives as μ/κ Opioid Receptor Dual Selective Ligands.Journal of medicinal chemistry · 2019Article
- Treating Opioid Dependence with Buprenorphine in the Safety Net: Critical Learning from Clinical Data.The journal of behavioral health services & research · 2017Article
- Kappa-Opioid Antagonists for Psychiatric Disorders: From Bench to Clinical Trials.Depression and anxiety · 2016Review
- Buprenorphine-elicited alteration of adenylate cyclase activity in human embryonic kidney 293 cells coexpressing κ-, μ-opioid and nociceptin receptors.Journal of cellular and molecular medicine · 2015Article
- Buprenorphine - an attractive opioid with underutilized potential in treatment of chronic pain.Journal of pain research · 2015Review
- Impact of research network participation on the adoption of buprenorphine for substance abuse treatment.Addictive behaviors · 2014Article
- Long term outcomes of pharmacological treatments for opioid dependence: does methadone still lead the pack?British journal of clinical pharmacology · 2014Review
- Utilizing buprenorphine-naloxone to treat illicit and prescription-opioid dependence.Neuropsychiatric disease and treatment · 2014Review
- Buprenorphine implant for opioid addiction.Pain management · 2012Article
- A novel approach in the detoxification of intravenous buprenorphine dependence.Indian journal of psychiatryArticle
- Post-operative Analgesia in Opioid Dependent Patients: Comparison of Intravenous Morphine and Sublingual Buprenorphine.Addiction & healthArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo review the current evidence on buprenorphine-naloxone for the treatment of opioid-related disorders, with a focus on primary care settings. QUALITY OF EVIDENCE: MEDLINE and the Cochrane Database of Systematic Reviews were searched. Evidence is mainly level I. MAIN MESSAGE: Buprenorphine is a partial μ-opioid agonist and κ-opioid antagonist with a long half-life and less abuse potential than methadone. For detoxification, buprenorphine is at least equivalent to methadone and is superior to clonidine. For maintenance treatment, buprenorphine is clearly superior to placebo. Methadone has a slight advantage in terms of retention in treatment, but a stepped approach with initial use of buprenorphine-naloxone is as efficacious. Use of buprenorphine in the primary care setting is feasible, safe, and effective. Authorization to prescribe buprenorphine can be obtained after completing online training.
conclusionBuprenorphine is a safe and effective agent for detoxification from opioids. It can be used as a first-line agent in maintenance programs, owing to its lower abuse potential relative to other opioids. Its effectiveness in primary care settings makes it a useful therapeutic tool for family physicians.
Indexed as
Identifiers
22267618PMC3264008W1913328868What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.